Edgewise Therapeutics Stock Options
| EWTX Stock | USD 18.11 0.07 0.39% |
Edgewise Therapeutics' option chain provides insight into all available option contracts written on Edgewise Therapeutics' stock. Investors can see outstanding put and call contracts with pricing information and greeks for a given expiration period. In addition, each of Edgewise Therapeutics' stock options below provides a detailed picture of the payoff. Comparing vital and dynamic information of various option contracts across diverse expiration periods will help you make an educated decision on your market timing strategies around investing in a given Edgewise option contract.
In The Money vs. Out of Money Option Contracts on Edgewise Therapeutics
Analyzing Edgewise Therapeutics' in-the-money options over time can help investors to take a profitable long position in Edgewise Therapeutics regardless of its overall volatility. This is especially true when Edgewise Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Edgewise Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Edgewise Therapeutics' stock while costing only a fraction of its price.
Edgewise Therapeutics' latest option contracts expiring on 2024-06-21 are carrying combined implied volatility of 78.68 with a put-to-call open interest ratio of 0.95 over 22 outstanding agreements suggesting investors are buying slightly more calls than puts on contracts expiring on 2024-06-21. The current put volume is at 8, with calls trading at the volume of 0. This yields a 0.0 put-to-call volume ratio. The Edgewise Therapeutics option chain provides detailed quote and price information for the current Edgewise Therapeutics option contracts. It shows all of Edgewise Therapeutics' listed puts, calls, expiration dates, strike prices, and other pricing information.
Open Interest Against 2024-06-21 Option Contracts
Edgewise Therapeutics option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Edgewise Therapeutics' lending market. For example, when Edgewise Therapeutics' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Edgewise Therapeutics, he or she must hedge the risk by shorting Edgewise Therapeutics stock over its option's life.
2024-06-21
The chart above shows Edgewise Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Edgewise Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Edgewise Therapeutics' option, there is no secondary market available for investors to trade.
Edgewise Therapeutics' stock options are financial instruments that give investors the right to buy or sell shares of Edgewise Therapeutics common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Edgewise stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Edgewise Therapeutics' stock price goes up or down, the stock options follow.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edgewise Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. Please note that buying 'in-the-money' options on Edgewise Therapeutics lessens the impact of time decay, as they carry both intrinsic and time value. So, even if Edgewise Therapeutics' value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money Edgewise Therapeutics contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if Edgewise Stock moves the wrong way.
At this time, Edgewise Therapeutics' Other Stockholder Equity is fairly stable compared to the past year. Stock Based Compensation is likely to rise to about 18.4 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 195.7 M in 2024. Edgewise Therapeutics In The Money Call Balance
When Edgewise Therapeutics' strike price is surpassing the current stock price, the option contract against Edgewise Therapeutics stock is said to be in the money. When it comes to buying Edgewise Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Edgewise Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Edgewise Current Options Market Mood
Edgewise Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Edgewise Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Most options investors, including buyers and sellers of Edgewise Therapeutics' calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. Edgewise Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction. Using current Edgewise Therapeutics' option volume and open interest to make an investment decision is considered a contrarian-sentiment measure that can be utilized in many timing strategies in both derivative and spot marketplace.
Rule 16 of the current Edgewise contract
Base on the Rule 16, the options market is currently suggesting that Edgewise Therapeutics will have an average daily up or down price movement of about 4.92% per day over the life of the 2024-06-21 option contract. With Edgewise Therapeutics trading at USD 18.11, that is roughly USD 0.89. If you think that the market is fully incorporating Edgewise Therapeutics' daily price movement you should consider buying Edgewise Therapeutics options at the current volatility level of 78.68%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Edgewise |
Purchasing Edgewise Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Edgewise calls. Remember, the seller must deliver Edgewise Therapeutics stock to the call owner when a call is exercised.
Edgewise Therapeutics Option Chain
When Edgewise Therapeutics' strike price is surpassing the current stock price, the option contract against Edgewise Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Edgewise Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Edgewise. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Edgewise. It also shows strike prices and maturity days for a Edgewise Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Delta | Gamma | Open Int | Expiration | Current Spread | Last Price | |||
Call | 2024-06-21 CALL at $2.5 | 0.9874 | 6.0E-4 | 0 | 2024-06-21 | 13.5 - 17.5 | 0.0 | In |
Call | 2024-06-21 CALL at $5.0 | 0.947 | 0.0033 | 0 | 2024-06-21 | 11.0 - 15.0 | 0.0 | In |
Call | 2024-06-21 CALL at $7.5 | 0.9089 | 0.0072 | 0 | 2024-06-21 | 8.5 - 12.5 | 0.0 | In |
Call | 2024-06-21 CALL at $10.0 | 0.8664 | 0.0128 | 0 | 2024-06-21 | 6.0 - 10.0 | 0.0 | In |
Call | 2024-06-21 CALL at $12.5 | 0.8121 | 0.0211 | 0 | 2024-06-21 | 3.5 - 7.6 | 0.0 | In |
Call | 2024-06-21 CALL at $15.0 | 0.7807 | 0.0521 | 1 | 2024-06-21 | 2.55 - 5.5 | 3.48 | In |
Call | 2024-06-21 CALL at $17.5 | 0.6106 | 0.0727 | 5 | 2024-06-21 | 1.25 - 3.6 | 4.45 | In |
Call | 2024-06-21 CALL at $20.0 | 0.4031 | 0.0845 | 19 | 2024-06-21 | 0.55 - 1.75 | 0.95 | Out |
Call | 2024-06-21 CALL at $22.5 | 0.2231 | 0.0686 | 12 | 2024-06-21 | 0.15 - 0.85 | 1.2 | Out |
Put | 2024-06-21 PUT at $30.0 | -0.8394 | 0.0324 | 0 | 2024-06-21 | 10.7 - 14.0 | 0.0 | In |
Put | 2024-06-21 PUT at $25.0 | -0.8299 | 0.0482 | 10 | 2024-06-21 | 5.0 - 9.5 | 4.9 | In |
Put | 2024-06-21 PUT at $22.5 | -0.7836 | 0.0687 | 7 | 2024-06-21 | 4.6 - 6.4 | 4.8 | In |
Put | 2024-06-21 PUT at $20.0 | -0.5442 | 0.0645 | 15 | 2024-06-21 | 2.25 - 4.9 | 3.1 | In |
Edgewise Total Stockholder Equity
Total Stockholder Equity |
|
Be your own money manager
Our tools can tell you how much better you can do entering a position in Edgewise Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Suggestion Now
Portfolio SuggestionGet suggestions outside of your existing asset allocation including your own model portfolios |
| All Next | Launch Module |
Edgewise Therapeutics Corporate Management
Elected by the shareholders, the Edgewise Therapeutics' board of directors comprises two types of representatives: Edgewise Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edgewise. The board's role is to monitor Edgewise Therapeutics' management team and ensure that shareholders' interests are well served. Edgewise Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edgewise Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Badreddin Edris | CoFounder Director | Profile | |
| John Moore | General Counsel | Profile | |
| Behrad Derakhshan | Chief Officer | Profile | |
| Marc MD | Chief Officer | Profile | |
| Alan Russell | Chief CoFounder | Profile |
Already Invested in Edgewise Therapeutics?
The danger of trading Edgewise Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Edgewise Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Edgewise Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Edgewise Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Edgewise Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edgewise Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edgewise Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edgewise Therapeutics Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edgewise Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Edgewise Stock analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Edgewise Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edgewise Therapeutics. If investors know Edgewise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edgewise Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.54) | Return On Assets (0.17) | Return On Equity (0.25) |
The market value of Edgewise Therapeutics is measured differently than its book value, which is the value of Edgewise that is recorded on the company's balance sheet. Investors also form their own opinion of Edgewise Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Edgewise Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edgewise Therapeutics' market value can be influenced by many factors that don't directly affect Edgewise Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edgewise Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edgewise Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edgewise Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.